Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NY-ESO-1 TCR Specific T cell Therapy in Bone and Soft Tissue Sarcoma
NCT03462316Phase 1Completed
- Sponsor
- Sun Yat-sen University
- Start
- May 2018
- Primary completion
- Apr 2020
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in bone sarcoma and soft tissue sarcoma (STS), sponsored by Sun Yat-sen University. Primary endpoint: Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v3.0 at 270 days. Started May 2018; status: completed.
02
Conditions
bone sarcomasoft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT03462316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03462316.